Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Raza, Azra ^a   Galili, Naomi ^a   Mulford, Deborah ^b   Smith, Scott E ^c   Brown, Gail L ^d   Steensma, David P ^e   Lyons, Roger M ^f   Boccia, Ralph ^g   Sekeres, Mikkael A ^h   Garcia Manero, Guillermo ⁱ   Mesa, Ruben A ^j  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d Telik Inc   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^g Center for Cancer and Blood Disorders   (United States)

^h TAUSSIG CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j MAYO CLINIC   (United States)

more..

Author keywords

Ezatiostat; Lenalidomide; MDS; Non deletion (5q); Phase 1

Indexed keywords

EZATIOSTAT; LENALIDOMIDE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTICLE; CHILL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSGEUSIA; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLANK PAIN; FLATULENCE; GASTRITIS; GOUT; HUMAN; HYPERSENSITIVITY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NON DELETION 5Q MYELODYSPLASTIC SYNDROME; NON DELETION MYELODYSPLASTIC SYNDROME; OCCULT BLOOD; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; SKIN ODOR; SWELLING; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DRUG THERAPY, COMBINATION; FEMALE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; THALIDOMIDE;

EID: 84865100331     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-18     Document Type: Article

References (17)

1. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Steensma DP, Tefferi A, Leuk Res 2003 27 95 120 10.1016/S0145-2126(02)00098-X 12526916
2. International scoring system for evaluating prognosis in myelodysplastic syndromes. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J, Blood 1997 89 2079 2088 9058730
3. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF, Blood 2008 111 86 93 10.1182/blood-2007-01-068833 17893227
4. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Laborde E, Cell Death Differ 2010 17 1373 1380 10.1038/cdd.2010.80 20596078
5. Novel Ezatiostat Analogues Disrupt Binding of GSTP1 to All Three Major MAP Kinases (JNK, ERK and p38) and Exhibit Context-Dependent Antitumor Activity [abstract]. Ali-Osman F, Okamura T, Turley R, Barker A, Keck JG, Laborde E, Cai D, Macsata R, Proceedings of the AACR-NCI-EORTC International Conference, San Francisco November 12-16, 2011 Abstract # B229
6. Induction of apoptosis by TLK199 in human leukemia cells [abstract]. Stofega M, Hsu SC, Chew J, Keck JG Brown G, Raza A, Cai D, Proceedings of the Annual Meeting of the American Association for Cancer Research, San Diego April 12-16, 2008 Abstract #2270
7. A Phase 2 Randomized Multicenter Study of 2 Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome. Raza A, Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Allison MA, Melnyk OG, Meng L, Jones M, Brown GL, Young S, Sekeres MA, Cancer 2011 10.1002/cncr.26469
8. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R, for the Myelodysplastic Syndrome-003 Study Investigators, New Eng J Med 2008 355 1456 1465
9. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, Blood 2000 96 3671 3674 11090046
10. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Bernasconi P, Br J Haematol 2009 142 695 708
11. Cytogenetics in acute leukemia. Mrozek K, Heerema N, Bloomfield C, Blood Rev 2004 18 115 136 10.1016/S0268-960X(03)00040-7 15010150
12. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H, Blood 2006 108 419 425 10.1182/blood-2005-10-4149 16609072
13. NCI Common Terminology Criteria for Adverse Events. Common Terminology Criteria for Adverse Events (CTCAE), 1-71. 3-31-2003. CTEP. Cancer Therapy Evaluation Program, Common Terminology Criteria Version 3.0 DCTD, NCI, NIH, DHHS, 2006 1
14. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M, Jones M, Keck JG, Meng L, Brown GL, List A, Blood 2009 113 6533 6540 10.1182/blood-2009-01-176032 19398716
15. Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure. Quddus F, Clima J, Seedham H, Sajjad G, Galili N, Raza A, J Hem Onc 2010 10.1186/1756-8722-3-16
16. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5Q. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, te Boekhorst P, Sanz G, del Cãizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E, Blood 2011 118 3765 3776 10.1182/blood-2011-01-330126 21753188
17. Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199) [abstract]. Galili N, Tamayo P, Botvinnik OB, Mesirov JP, Zikria J, Brown G, Raza A, Proceedings of the American Society of Hematology, San Diego December 10-13, 2011 Abstract #2779